6-alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds

Journal of Medicinal Chemistry

Volumn 56, Issue 24, 2013, Pages 9874-9896

  Röver, Stephan ^a   Andjelkovic, Mirjana ^a   Bénardeau, Agnès ^a   Chaput, Evelyne ^a   Guba, Wolfgang ^a   Hebeisen, Paul ^a   Mohr, Susanne ^a   Nettekoven, Matthias ^a   Obst, Ulrike ^a   Richter, Wolfgang F ^a   Ullmer, Christoph ^a   Waldmeier, Pius ^a   Wright, Matthew B ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 6 (CYCLOPROPYLMETHOXY) N (2 HYDROXYCYCLOHEXYL) 3 PYRIDINECARBOXAMIDE; 5 (4 CHLOROPHENYL) N (2 HYDROXYCYCLOHEXYL) 6 (2 METHOXYETHOXY) 3 PYRIDINECARBOXAMIDE; CANNABINOID 1 RECEPTOR ANTAGONIST; PYRIDINECARBOXAMIDE DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG STRUCTURE; DRUG SYNTHESIS; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OBESITY; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT GAIN;

EID: 84891285302     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4010708     Document Type: Article

References (46)

1. Touwn, M. The religious and medicinal uses of Cannabis in China, India and Tibet J. Psychoactive Drugs 1981, 13, 23-34
2. Gaoni, Y.; Mechoulam, R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish J. Am. Chem. Soc. 1964, 86, 1646-1647
3. Devane, W. A.; Dysarz, F. A., III; Johnson, M. R.; Melvin, L. S.; Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol. 1988, 34, 605-613
4. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990, 346, 561-564
5. Gerard, C.; Mollereau, C.; Vassart, G.; Parmentier, M. Nucleotide sequence of a human cannabinoid receptor cDNA Nucleic Acids Res. 1990, 18, 7142
6. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids Nature 1993, 365, 61-65
7. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 1992, 258, 1946-1949
8. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem. Biophys. Res. Commun. 1995, 215, 89-97
9. Pacher, P.; Bátkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol. Rev. 2006, 58, 389-462
10. Guindon, J.; Hohmann, A. G. The endocannabinoid system and cancer: therapeutic implication Br. J. Pharmacol. 2011, 163, 1447-1463
11. Mallat, A.; Teixeira-Clerc, F.; Deveaux, V.; Manin, S.; Lotersztajn, S. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings Br. J. Pharmacol. 2011, 163, 1432-1440
12. Montecucco, F.; Di Marzo, V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction Trends Pharmacol. Sci. 2012, 33, 331-340
13. Abood, M.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Cravatt, B. F.; Devane, W. A.; Elphick, M. R.; Felder, C. C.; Herkenham, M.; Howlett, A. C.; Kunos, G.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G. Cannabinoid receptors: CB1 receptor. IUPHAR database (IUPHAR-DB); International Union of Basic and Clinical Pharmacology: Kansas City, Kansas, 2013; http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=56 and references cited therein.
14. Janero, D. R.; Makriyannis, A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Expert Opin. Emerging Drugs 2009, 14, 43-65
15. Sam, A. H.; Salem, V.; Ghatei, M. A. Rimonabant: From RIO to Ban. J. Obes. 2011, Article ID 432607.
16. FDA Briefing Document NDA 21-888, Zimulti (rimonabant) Tablets, 20 mg, Sanofi Aventis, Advisory Committee; U.S. Food and Drug Administration: Silver Spring, MD, June 13, 2007; http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007- 4306b1-fda-backgrounder.pdf
17. Proietto, J.; Rissanen, A.; Harp, J. B.; Erondu, N.; Yu, Q.; Suryawanshi, S.; Jones, M. E.; Johnson-Levonas, A. O.; Heymsfield, S. B.; Kaufman, K. D.; Amatruda, J. M. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study Int. J. Obes. 2010, 34, 1243-1254
18. Aronne, L. J.; Finer, N.; Hollander, P. A.; England, R. D.; Klioze, S. S.; Chew, R. D.; Fountaine, R. J.; Powell, C. M.; Obourn, J. D. Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance Obesity 2011, 19, 1404-1414
19. Fulp, A.; Bortoff, K.; Seltzman, H.; Zhang, Y.; Mathews, J.; Snyder, R.; Fenell, T.; Maitra, R. Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity J. Med. Chem. 2012, 55, 2820-2834
20. Tam, J.; Vemuri, V. K.; Liu, J.; Batkai, S.; Mukhopadhyay, B.; Godlewski, G.; Osei-Hyiaman, D.; Ohnuma, S.; Ambudkar, S. V.; Pickel, J.; Makriyannis, A.; Kunos, G. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity J. Clin. Invest. 2010, 120, 3735-3735
21. Tarzia, G.; LoVerme, J.; Duranti, A.; Tontini, A.; Spadoni, G.; Mor, M.; Rivara, S.; Stella, N.; Xu, C.; Piomelli, D. Synthesis and characterization of a peripherally restricted CB(1) cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice Bioorg. Med. Chem. Lett. 2009, 19, 639-643
22. Barth, F.; Hortala, L.; Rinaldi-Carmona, M.; Congy, C.; Boulu, L.; Sadoun, F.; Fabre, G.; Finance, O. Rational design of a novel peripherally restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif Bioorg. Med. Chem. Lett. 2010, 20, 4573-4577
23. Hogberg, T.; Receveur, J. M.; Murray, A.; Linget, J. M.; Norregaard, P. K.; Cooper, M.; Bjurling, E.; Nielsen, P. A. Conversion of 4-cyanomethyl- pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain barrier Bioorg. Med. Chem. Lett. 2010, 20, 453-457
24. Hogberg, T.; Cooper, M.; Receveur, J. M.; Bjurling, E.; Norregaard, P. K.; Nielsen, P. A.; Skold, N. Exploring SAR features in diverse library of 4-cyanomethylpyrazole-3-carboxamides suitable for further elaborations as CB1 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 26-30
25. Sasmal, P. K.; Reddy, D. S.; Talwar, R.; Venkatesham, B.; Balasubrahmanyam, D.; Kannan, M.; Srinivas, P.; Kumar, K. S.; Devi, B. N.; Jadhav, V. P.; Khan, S. K.; Mohan, P.; Chaudhury, H.; Bhuniya, D.; Iqbal, J.; Chakrabarti, R. Novel pyrazole-3-carboxamide derivatives as cannabinoid-1 (CB1) antagonists: journey from non-polar to polar amides Bioorg. Med. Chem. Lett. 2011, 21, 562-568
26. Dow, L. D.; Carpino, P. A.; Gautreau, D.; Hadcock, J. R.; Iredale, P. A.; Kelly-Sullivan, D.; Lizano, J. S.; O'Connor, R. E.; Schneider, S. R.; Scott, D. A.; Ward, K. A. Design of a potent CB1 receptor antagonist series: potential scaffold for peripherally-targeted agents ACS Med. Chem. Lett. 2012, 3, 397-401
27. Mayweg, A.; Marty, H. P.; Mueller, W.; Narquizian, R.; Neidhart, W.; Pflieger, P.; Roever, S. Novel CB1 receptor inverse agonists. WO 2004060870 A1, 2004.
28. Kuo, G.-H.; Prouty, C.; Wang, A.; Emanuel, S.; DeAngelis, A.; Zhang, Y.; Song, F.; Beall, L.; Connolly, P. J.; Karnachi, P.; Chen, X.; Gruninger, R. H.; Sechler, J.; Fuentes-Pesquera, A.; Middleton, S. A.; Jolliffe, L.; Murray, W. V. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors J. Med. Chem. 2005, 48, 4892-4909
29. Andjelkovic, M.; Benardeau, A.; Chaput, E.; Hebeisen, P.; Nettekoven, M.; Obst Sander, U.; Panousis, C. G.; Roever, S. 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents. WO 2008040651 A1, 2008.
30. Wishka, D. G.; Graber, D. R.; Seest, E. P.; Dolak, L. A.; Han, F.; Watt, W.; Morris, J. Stereoselective Synthesis of Furo[2,3- c ]pyridine Pyrimidine Thioethers, A New Class of Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors J. Org. Chem. 1998, 63, 7851-7859
31. Alig, L.; Alsenz, J.; Andjelkovic, M.; Bendels, S.; Bénardeau, A.; Bleicher, K.; Bourson, A.; David-Pierson, P.; Guba, W.; Hildbrand, S.; Kube, D.; Lübbers, T.; Mayweg, A. V.; Narquizian, R.; Neidhart, W.; Nettekoven, M.; Plancher, J.-M.; Rocha, R.; Rogers-Evans, M.; Röver, S.; Schneider, G.; Taylor, S.; Waldmeier, P. Benzodioxoles: Novel Cannabinoid-1 Receptor Inverse Agonists for the Treatment of Obesity J. Med. Chem. 2008, 51, 2115-2127
32. Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular Hydrogen Bonding in Medicinal Chemistry J. Med. Chem. 2010, 53, 2601-2611
33. Data for rimonabant can be found in the registration dossiers, e.g.: Scientific Discussion; European Medicines Agency: London, 2006; http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000666/WC500021284.pdf
34. Flamment, M.; Gueguen, N.; Wetterwald, C.; Simard, G.; Malthièry, Y.; Ducluzeau, P. H. Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet Am. J. Physiol. Endocrinol. Metab. 2009, 297, E1162-E1170
35. Ahima, R. S.; Flier, J. S. Adipose Tissue as an Endocrine Organ Trends Endocrinol. Metab. 2000, 11, 327-332
36. Poirier, B.; Bidouard, J.-P.; Cadrouvele, C.; Marniquet, X.; Staels, B.; O'Connor, S. E.; Janiak, P.; Herbert, J.-M. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile Diabetes, Obes. Metab. 2005, 7, 65-72
37. Macedo, I. C.; Medeiros, L. F.; Oliveira, C.; Oliveira, C. M.; Rozisky, J. R.; Scarabelot, V. L.; Souza, A.; Silva, F. R.; Santos, V. S.; Cioato, S. G.; Caumo, W.; Torres, I. L. Cafeteria diet-induced obesity plus chronic stress alter serum leptin levels Peptides 2012, 38, 189-196
38. Chen, R. Z.; Frassetto, A.; Lao, J. Z.; Huang, R. R.; Xiao, J. C.; Clements, M. J.; Walsh, T. F.; Hale, J. J.; Wang, J.; Tong, X.; Fong, T. M. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor Eur. J. Pharmacol. 2008, 584, 338-342
39. Cluny, N. L.; Vemuri, V. K.; Chambers, A. P.; Limebeer, C. L.; Bedard, H.; Wood, J. T.; Lutz, B.; Zimmer, A.; Parker, L. A.; Makriyannis, A.; Sharkey, K. A. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents Br. J. Pharmacol. 2010, 161, 629-642
40. Tam, J.; Cinar, R.; Liu, J.; Godlewski, G.; Wesley, D.; Jourdan, T.; Szanda, G.; Mukhopadhyay, B.; Chedester, L.; Liow, J. S.; Innis, R. B.; Cheng, K.; Rice, K. C.; Deschamps, J. R.; Chorvat, R. J.; McElroy, J. F.; Kunos, G. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance Cell Metab. 2012, 16, 167-179
41. Pang, Z.; Wu, N. N.; Zhao, W.; Chain, D. C.; Schaffer, E.; Zhang, X.; Yamdagni, P.; Palejwala, V. A.; Fan, C.; Favara, S. G.; Dressler, H. M.; Economides, K. D.; Weinstock, D.; Cavallo, J. S.; Naimi, S.; Galzin, A. M.; Guillot, E.; Pruniaux, M. P.; Tocci, M. J.; Polites, H. G. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice Obesity 2011, 19, 1923-1934
42. Quarta, C.; Bellocchio, L.; Mancini, G.; Mazza, R.; Cervino, C.; Braulke, L. J.; Fekete, C.; Latorre, R.; Nanni, C.; Bucci, M.; Clemens, L. E.; Heldmaier, G.; Watanabe, W.; Leste-Lassere, T.; Maitre, M.; Tedesco, L.; Fanelli, F.; Reuss, S.; Klaus, S.; Srivastava, R. K.; Monory, K.; Valerio, A.; Grandis, A.; De Giorgio, R.; Pasquali, R.; Nisoli, E.; Cota, D.; Lutz, B.; Marsicano, G.; Pagotto, U. CB1 Signaling in Forebrain and Sympathetic Neurons Is a Key Determinant of Endocannabinoid Actions on Energy Balance Cell Metab. 2010, 11, 273-285
43. Mukhopadhyay, P.; Rajesh, M.; Bátkai, S.; Patel, V.; Kashiwaya, Y.; Liaudet, L.; Evgenov, O. V.; Mackie, K.; Haskó, G.; Pacher, P. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes Cardiovasc. Res. 2010, 85, 773-784
44. Cusack, K. P.; Breinlinger, E. C.; Fix-Stenzel, S.-R.; Stoffel, R. H.; Woller, K. R. Novel oxadiazole compounds. WO 2011071570 A1, 2011.
45. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
46. Seglen, P. O. Preparation of isolated rat liver cells Methods Cell Biol. 1976, 13, 29-83